Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Sep 30;9(6):1109–1120. doi: 10.1002/jcsm.12346

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Diameter of control (ctrl), C26 CM, and C26^Lif−/− CM‐treated myotubes. (A) Measurements made at 0 (day 4), and 24, 48, and 72 h of treatment with C26 CM or C26^Lif−/− CM. At least 100 myotubes were measured per group. (B) Measurement of fluorescent myotubes after immunocytochemistry at 72 h treatment. (C) Representative images of fluorescent myotubes from 72 h control, C26 CM, and C26^Lif−/− CM‐treated groups. ^*Significantly different from control value at same time point (P < 0.05). ^†Significantly different from C26 value (P < 0.05).